Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1486)	10/24/2002 2:30:11 PM
From: keokalani'nui	Respond to of 2243

>>And why is this shocking (not!) immunogenicity just now -- after such an extended period of human testing -- coming to light?<< Exactly.

To: scaram(o)uche who wrote (1486)	10/24/2002 2:31:52 PM
From: tuck	Read Replies (1) \| Respond to of 2243

>>And why is this shocking (not!) immunogenicity just now -- after such an extended period of human testing -- coming to light?<< Indeed. A quick flip through PubMed got me a PII study of BTI-322 for GVHD (n=26). Dosing was probably different, population definitely so, bit FWIW, the relevant snips: "BTI-322 0.1 mg/kg rounded up to the nearest milligram was administered intravenously (IV) daily for 10 consecutive days." "No IgG or IgM anti-BTI-322 antibodies were found in the 26 samples tested after therapy." I join you in saying grrrrr. This is not a current holding for me, but it is for my Mom. Thank goodness I got ABSC right for her. Tempting to bottom fish BTRN for SCS alone. Cheers, Tuck